HIV Antiretroviral Therapy (ART) AdherenceReengagementNCT06803316
Optimizing Care Delivery to Support Reengagement in PLWH Returning to HIV Care After Treatment Lapses in Zambia
An observational study of HIV Antiretroviral Therapy (ART) Adherence, run by Centre for Infectious Disease Research in Zambia at 1 site in Zambia.
Trial summary
1.0 Introduction The scale-up of human immunodeficiency virus (HIV) treatment services has expanded rapidly in Zambia, facilitated by evolution of the HIV response from centralized services to decentralized care and now towards differentiated service delivery models. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV Antiretroviral Therapy (ART) Adherence
- How many people
- 658 participants
- Where
- 1 siteZambia
- Study dates
- 10 Aug 2022to 31 Jul 2025
- How long will I take part?
- 308 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient Semi-Structured Interviews: We will recruit PLWH (age≥18 years) who reengaged in care within the past 6 months at four health care facilities supported by CIDRZ in Lusaka and subsequently did (n=15) and did not (n=15) remain in care. We will recruit individuals amongst our survey cohort who agreed to be contacted in the future for qualitative interviews. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 30 days late to their last appointment per Zambian HIV guidelines and or not having ART drugs for greater than 30 days. Healthcare workers: The target population for this objective are all health care workers involved in delivery HIV care at our study facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. We use convenience sampling to identify HCW for in-depth interviews (IDIs) (i.e., clinicians, nurses,
Who may be able to join
- Participant must be over 18 years of age.
- Should be LTFU for greater than 30 days or
- Should not have had ART drugs for greater than 30 days;
- Pregnant women who meet inclusion criteria
- Illiterate participants willing to provide informed consent in Nyanja or Bemba provided there is a witness.
Who cannot join
- Participant is too sick i.e., failing to talk, general discomfort and emergency cases).
- Participant is unable to provide written informed consent in English, Nyanja or Bemba.
- Participant who is drunk or mentally ill.
- -
Trial locations and contacts
1 site in 1 country.
Zambia1 site
Centre for Infectious Disease Research in Zambia (CIDRZ)
Lusaka, Lusaka Province, 10101
About this study
1.0 Introduction
The scale-up of human immunodeficiency virus (HIV) treatment services has expanded rapidly in Zambia, facilitated by evolution of the HIV response from centralized services to decentralized care and now towards differentiated service delivery models. Nevertheless, optimal effectiveness remains elusive because timely engagement in care to allow uninterrupted access to antiretroviral therapy (ART) and sustained viral suppression remain incomplete. Ensuring retention in care is especially relevant since greater numbers of HIV-infected patients are also entering a phase of long-term follow-up. After receiving access to HIV care, a high fraction become lost to follow up with some estimates as high as 25-40%, which is defined as the outcome where the patient has missed their appointment by 30 days and has not died or seeking care at a different healthcare facility, or disengaged from care altogether. Research also suggests that LTFU outcomes are driven by a multitude of factors including structural and clinic-based barriers, individual and community-based barriers. A new generation of innovative interventions is needed to overcome these multifaceted barriers to optimization of the engagement of HIV infected patients with the public health systems that have emerged to serve them. Sustained retention is a critical determinant of viral suppression for PLWH, but treatment interruptions put them at high risk for viremia and mortality.
Read more
Emerging evidence clearly demonstrates that people living with HIV (PLWH) frequently transition in and out of care over time in sub-Saharan Africa and the time of re-engagement in HIV care presents a critical opportunity to break these ongoing cycles of disengagement. Since the presence of specific barriers leads to disengagement from care for some patients, designing strategies targeting these barriers can offer up a natural prospect for ensuring long-term care engagement. It is evident that the strategies required to initiate a patient into care would be markedly different than those to ensure reengagement in care. Even when PLWH return to care after loss to follow-up (LTFU), rates of repeat LTFU in the future are very high. Our preliminary data from Zambia suggests that 30% become LTFU again within 6 months of return, and that 50% of those who are currently LTFU have previously cycled in and out of care. Few interventions have successfully improved return rates among those LTFU but an estimated 50-70% return to care on their own by one year. Strategies for intervening at the time of reengagement in care are urgently needed to break these cycles of disengagement in this high-risk population.
To address these knowledge gaps, we seek to engage key stakeholders in developing a reengagement program to address critical barriers to reengagement and strengthen long-term reengagement in care. This reengagement study will provide important direction for future interventions and studies to formally test this health-system intervention for patients reengaging in HIV care after LTFU.
1.1 Rationale
Evidence from our groups as well as throughout Africa highlight the critical needs to strengthen programs for reengagement into HIV care. It is well documented that PLWH frequently transition in and out of care over time in sub-Saharan Africa leading to treatment interruptions that can put them at high risk for viremia and mortality. Among those who return to care after loss to follow-up (LTFU), rates of repeat LTFU in the future are also very high with up to 30% becoming LTFU again within 6 months of return. Additionally, among those who are currently LTFU, 50% have previously cycled in and out of care indicating missed opportunities to intervene. As an estimated 50-70% of those LTFU return to care on their own by one year strategies for intervening at the time of reengagement in care are very promising to help break these cycles of disengagement in this high-risk population.
1.2 Research Question
What are the most important needs and preferences of patients and providers for a multicomponent reengagement strategy?
2.0 Study Objectives
2.1 Study Specific Aim
To develop a reengagement strategy that meets the needs and preferences of patients and providers in public health HIV settings.
2.2 Scientific Objectives
The study has three main objectives. These include:
- Assess patient and provider needs and preferences for reengagement strategies using best-worse scaling experiments.
- Assess patient and provider needs and preferences for reengagement strategies using qualitative methods.
- Develop an intervention to optimize the experience of reengagement in HIV care using human-centered design.
Read the detailed description
Purpose of the research: To systematically evaluate the overall patient experience and its effect on retention in care and virologic suppression via multiple novel measurement modalities in public ART clinics in Zambia and make public health HIV treatment more patient centred, manage and enhance perceptions of quality, and strengthen engagement to optimize treatment.
Statement of the problem: Evidence from our previous Betterinfo study (004-06-14) as well as throughout sub-Saharan Africa points to patient experience as a crucial area for improvement. These data offer a simple synthesis and strategy for improvements. That is, when patients perceive encounters with the health system to be high-quality, respectful, accessible, responsive, and effective, engagement is strengthened.
Rationale/Justification for the study: This study will provide important direction for future interventions to implement more patient-centred care in the current public health HIV infrastructure, as it will fill important knowledge gaps regarding clinic-based barriers to care.
Research questions:
- What are the most important needs and preferences of patients and providers for a multicomponent reengagement strategy?
Main Aim: To develop a reengagement strategy that meets the needs and preferences of patients and providers in public health HIV settings.
Specific objectives: The study has three main objectives. These include:
- Assess patient and provider needs and preferences for reengagement strategies using best-worse scaling experiments.
- Assess patient and provider needs and preferences for reengagement strategies using qualitative methods.
- Develop an intervention to optimize the experience of reengagement in HIV care using human-centered design.
Methodology (design, sampling, data collection methods and tools):
Objective 1: Investigators will conduct best-worse scaling experiments among patients (n=400) and HCWs (n=200) to quantify relative preferences for the contents and implementation attributes for strategies to improve post-return care delivery.
Objective 2: Guided by the Consolidated Framework for Implementation Research and the Socioecological Model, investigators will use qualitative methods to explore how to optimize the experiences of care delivery after returning to HIV care. Investigators will conduct semi-structured interviews with PLWH who reengaged in the past 6 months and did (n=15) and did not (n=15) remain in care as well as focus group discussions with HCWs (i.e., physicians, nurses, clinic leadership; 6 FGDs, n=8-10 each)
Objective 3: Using principles from human-centered design and intervention mapping, investigators will synthesize findings from Aim 1 and co-develop a multicomponent reengagement coordination implementation strategy focused on:
- improving the patient experience of reengagement,
- optimizing ART re-initiation and viral load monitoring post-return, and
- offering services tailored to initial LTFU reasons to support sustained engagement.
Investigators will employ an iterative human-centered process involving key stakeholders (reengaged PLWH, HCWs, clinic leadership, Ministry of Health) to co-design the key components (e.g., practice facilitation and audit-feedback for providers, tailored services for patients) and develop a locally appropriate and acceptable intervention prototype.
Data management issues (data management plan, analysis and storage):
Objective 1: Investigators will summarize routine survey responses using frequency and proportions. Investigators will evaluate the BWS exercise using count analysis and BWS scores for individuals (difference in number of times item scored best and worst/number of times item appears) and, aggregate score for the population (mean population score f rescaled to 100, presented as forest plots). Investigators will use standard statistical techniques to explore preference heterogeneity and will perform subgroups analyses across characteristics including reason for initial LTFU (i.e., structural, clinic-based, psychosocial), sex, age, and HCW cadre. Data will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Data will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Once data are linked to SmartCare records using ART numbers, identifying information will be removed in order to maintain confidentiality.
Objective 2: Recordings will be transcribed by trained CIDRZ RAs, and if necessary, translated into English with subsequent back translation or a second-party review of sections of the translation. With the transcribed audio-recording data, investigators will code and computerize for analysis. The audio recordings, data collection tools and memos will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Identifying information will be removed during transcription in order to maintain confidentiality. Transcriptions will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Investigators will use thematic content analysis across all data to analyze the data using qualitative software (e.g. Dedoose or NVivo). Qualitative data analysis consists of searching for patterns in data and conceptualizing ideas that help explain the presence of those patterns. For patient interviews, investigators will also employ a narrative analysis where we read each interview as a whole, without regard to individual codes, to create a more global understanding of the "point of the story".
Objective 3: Implementation of HCD generally follows an iterative framework of inquiry, problem-solving and co-design. Diverse methods are employed in each of these phases including system/stakeholder mapping, compiling secondary data, user journey maps/personas, cognitive sorting and ranking, and iterative prototyping. Investigators will collect detailed meeting minutes, visual outputs created from participatory activities, written reflections from participants, and take careful notes during the design team meetings and workshops. Investigators will qualitatively analyze data gathered during the HCD co-creation activities using affinity mapping and rapid thematic analysis. This will occur in between co-creation workshops to identify design opportunities to discuss in future workshops and also after the close of the final workshop.
Participants to be recruited and inclusion criteria: This study will be conducted in Lusaka province at four Ministry of Health-operated facilities that are supported by the Centre for Infectious Disease Research in Zambia (CIDRZ). All participants must give consent to participate. Additional inclusion criteria, sampling and sample size are as follows:
Objective 1 PLHW reengaging in HIV care: Investigators will enroll up to 400 PLWH (age≥18 years) who are reengaging in care from four health care facilities supported by CIDRZ in Lusaka. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 60 days late to their last appointment per Zambian HIV guidelines. Investigators will include PLWH returning to their original clinic or as a transfer from a different facility. Investigators will recruit participants on the day of return to care using similar recruitment procedures as Objective 1. Eligible participants will be identified by clinical staff during their routine clinic visit, and trained CIDRZ research assistants (RAs) will then recruit and enroll them in a private area as they wait for their clinical consultation or drug pick-up. Investigators have used this approach to successfully recruit over 300 returning patients to date as part of an ongoing study (BMFG OPP1166485).
Healthcare Workers: Investigators will enroll up to 200 health care workers who participate in the care of PLWH across these four health care facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. Investigators will use convenience sampling to identify HCW for surveys using procedures that have been well-established by our study team in Zambia to successfully recruit HCWs. Investigators will first engage with clinic leadership to identify appropriate times for recruitment and survey administration.
Objective 2 Patient Semi-Structured Interviews: Investigators will recruit PLWH (age≥18 years) who reengaged in care within the past 6 months at four health care facilities supported by CIDRZ in Lusaka and subsequently did (n=15) and did not (n=15) remain in care. Investigators will recruit individuals amongst our survey cohort who agreed to be contacted in the future for qualitative interviews. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 60 days late to their last appointment per Zambian HIV guidelines. Investigators will include PLWH returning to their original clinic or as a transfer from a different facility. Investigators will use purposive and maximum variation sampling of participants to ensure participants represent a range of perspectives (i.e., we will recruit participants based on patient characteristics such as gender and age to ensure a range of perspectives as well as barriers to care identified during surveys in Objective 1).
Eligible participants who remained in care will be identified by clinical staff during their routine clinic visit, and trained CIDRZ research assistants (RAs) will then recruit and enroll them in a private area. Those who become LTFU within 6-months of return will be identified in the EHR, through clinic logs, and through routine tracing procedures already in place. These individuals will be contacted via phone and recruited; if they agree to participate, they will then be interviewed in-person in mutually agreed private location. Our research team and CIDRZ has previously used these procedures to recruit LTFU participants for in-depth interviews.
Healthcare workers: The target population for this objective are all health care workers delivery HIV care at our study facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. Investigators will use convenience sampling to identify HCW for focus groups discussions among HCWs (i.e., clinicians, nurses, lay HCWs, pharmacists, clinic leadership) at four facilities. Investigators will use procedures that have been well-established by our study team in Zambia to successfully recruit HCWs. Investigators will first engage with clinic leadership to identify appropriate times for recruitment and interviews. Investigators will conduct 6 FGDs (N=8-10 each), which will be organized by HCW cadre to ensure that there is open discussion with minimal concern for power hierarchies.
Objective 3 Investigators will recruit reengaged patients (beneficiaries) and HCWs (implementers). Informed by Aim 1 findings, investigators will also use stakeholder mapping to identify key groups who may influence reengagement behaviors and outcomes among PLWH and HCWs and purposefully recruit from these groups from the four facilities in Aim 1. A priori, we expect to engage with patients who have reengaged in care (n=5-10), health care workers (n=5-10) (as beneficiaries and implementers, respectively, of the interventions) and clinic leadership (n=5) and Ministry of Health administrators (n=1-2) as influencers. Our team has experience recruiting and engaging these multilevel stakeholders in HCD workshops82. Recruitment will be similar to procedures outlined in previous objectives. Participants will be given K100 for travel reimbursement.
Ethical considerations: Investigators will submit the proposed protocol, the informed consent documents, data collection tools and any subsequent modifications for review and approval. Also, the Washington University School of Medicine (WUSM) Institutional Review Board (IRB) will provide ethical reviews and regulatory oversight through a reliance agreement with the other collaborating US institutions. Investigators request an expedited review and will obtain written informed consent from participants agreeing to participate in the following study activities:
- Patient Surveys and In-depth Interviews with patients.
- Health care worker surveys and Focus group discussions
Permission will be sought from national, provincial, district and facility Ministry of Health authorities to conduct the study in public health facilities. The study will follow standard Ministry of Health guidelines to engage with staff, patients and patient records. Investigators will also ensure that all staff involved with study data are trained in Good Clinical Practice and Human Subjects Protection.
Timelines: The study proposes to implement the study intervention over a course of 18 months. Detailed timeline with activities are outlined in the proposed protocol.
Plans to disseminate research findings:
In-order to maximise the benefit of the study findings without delay, the study findings will be shared with key stakeholders such as Ministry of Health and community leaders. Study findings will be disseminated at national, international meetings, conferences and in scientific journals. Permission will be sought from National Health Research Authority prior to any publications or any form of dissemination being made.
POSSIBLE BENEFITS TO PARTICIPANTS:
No direct benefits to participants are expected. Participants may benefit in that the aim provides a direct outlet for their input to be translated into intervention design and future policy decisions. Participants may benefit from improvements in quality of care provided and increased understanding from health care workers resulting from this work. Those disengaged from care may benefit from tracing and follow up by trained counsellors and may decide to re-engage in care. Participants will also receive a small reimbursement (approximately K 100) for their transport and time spent to participate in semi-structured interviews or FGDs. Health care workers and facilities may benefit from understanding patient expectations and from learning how data can be used to interpret and improve clinic practices. Patients may also benefit from the knowledge that their perspectives are valued for improving care delivery. The Zambian Ministry of Health will benefit from the coaching provided by the research team, which may serve to improve the working environment for health care workers and care delivered to patients. The HCD process will result in developing a reengagement strategy that can improve the care of people living with HIV.
POSSIBLE RISKS TO PARTICIPANTS:
All interviews and discussion have the potential to make participants embarrassed, worried, anxious, or uncomfortable when reporting on their interactions. Participants may feel uncomfortable answering questions or discussing their HIV treatment history with the research team during semi-structured interviews or when completed surveys. The research staff will be trained to be sensitive to these areas, for example, such as discussing challenges with HIV care, livelihoods, or family. HCWs may similarly experience discomfort discussing or answering surveys pertinent to their own skills or work preferences. Some participants who are currently lost from care may be contacted via telephone to participate in interviews. This contact may have a small possible risk of involuntary disclosure of HIV status. Investigators will attempt to minimize this by training all follow up staff to be discrete and professional, ensuring that patient confidentiality is maintained at all times and identities are verified prior to providing additional information.
During FGDs, colleagues may also be present and HCWs may fear reprisal if confidentiality is breached. FGDs will be organized by HCW cadre to be sensitive of power dynamics and ensure comfort in openly discussing pertinent topics.
Participants in HCD workshops may also feel uncomfortable answering questions and participating in discussions regarding the challenges about receiving and/or delivering HIV care. Patients may fear negative attitudes from HCWs and HCWs may worry about retribution from their superiors. Workshop composition will be attentive to power dynamics, ensuring participants are engaged on days of the workshop or through sub-groups such that they are free to share their opinions and act as co-designers (e.g., patients or HCWs feel free to share thoughts in presence of health care administrators).
Details of how these risks will be minimized are outlined in the protocol.
POSSIBLE BENEFITS TO THE COMMUNITY:
The potential benefits to society may be an increased understanding of how the process of reengagement can be improved to facilitate ongoing sustained engagement in care and overall HIV outcomes and the needs and preferences of key stakeholders.
- Keywords
- HIV, Antiretroviral Therapy (ART), Retention, Reengagement
What is being measured
The primary outcome is the main question the study is designed to answer.
Retention
Number of participants who reengaged (less than 30 days late to their scheduled appointments) and were consistently taking their medication
Measured: 2022 to 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2025
- Study start10 Aug 2022
- Primary completion31 Jul 2025
- Study completion31 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (85)Papers the sponsor has linked to this study.
- Other trials for HIV Antiretroviral Therapy (ART) AdherenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 658 participants (actual)
- Target duration
- 308 Days
Sponsor and investigators
- Lead sponsor
- Centre for Infectious Disease Research in Zambia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Izukanji Sikazwe, Medical Officer, Principal investigator, Centre for Infectious Disease Research in Zambia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06803316
- Sponsor's protocol ID
- REENGAGEMENT (R34)
- Other IDs
- 1R34MH129219-01A1
- Acronym
- Reengagement
- Status last verified
- Aug 2026
- First submitted
- 27 Jan 2025
- Last updated
- 12 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Data will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Once data are linked to SmartCare records using ART numbers, identifying information will be removed in order to maintain confidentiality. Similarly, transcriptions will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis.
Publications
Vindrola-Padros C, Johnson GA. Rapid Techniques in Qualitative Research: A Critical Review of the Literature. Qual Health Res. 2020 Aug;30(10):1596-1604. doi: 10.1177/1049732320921835.
PubMed 32667277Koenig CJ, Abraham T, Zamora KA, Hill C, Kelly PA, Uddo M, Hamilton M, Pyne JM, Seal KH. Pre-Implementation Strategies to Adapt and Implement a Veteran Peer Coaching Intervention to Improve Mental Health Treatment Engagement Among Rural Veterans. J Rural Health. 2016 Sep;32(4):418-428. doi: 10.1111/jrh.12201. Epub 2016 Aug 10.
PubMed 27509291Higginbottom GM. Sampling issues in qualitative research. Nurse Res. 2004;12(1):7-19. doi: 10.7748/nr2004.07.12.1.7.c5927.
PubMed 15493211Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Health. 2015 Sep;42(5):533-44. doi: 10.1007/s10488-013-0528-y.
PubMed 24193818Roy M, Holmes C, Sikazwe I, Savory T, Mwanza MW, Bolton Moore C, Mulenga K, Czaicki N, Glidden DV, Padian N, Geng E. Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia. Clin Infect Dis. 2018 Sep 28;67(8):1269-1277. doi: 10.1093/cid/ciy285.
PubMed 29635466Holmes CB, Sikazwe I, Sikombe K, Eshun-Wilson I, Czaicki N, Beres LK, Mukamba N, Simbeza S, Bolton Moore C, Hantuba C, Mwaba P, Phiri C, Padian N, Glidden DV, Geng E. Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey. PLoS Med. 2018 Jan 12;15(1):e1002489. doi: 10.1371/journal.pmed.1002489. eCollection 2018 Jan.
PubMed 29329301Mody A, Roy M, Sikombe K, Savory T, Holmes C, Bolton-Moore C, Padian N, Sikazwe I, Geng E. Improved Retention With 6-Month Clinic Return Intervals for Stable Human Immunodeficiency Virus-Infected Patients in Zambia. Clin Infect Dis. 2018 Jan 6;66(2):237-243. doi: 10.1093/cid/cix756.
PubMed 29020295Mody A, Sikazwe I, Czaicki NL, Wa Mwanza M, Savory T, Sikombe K, Beres LK, Somwe P, Roy M, Pry JM, Padian N, Bolton-Moore C, Holmes CB, Geng EH. Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia. PLoS Med. 2018 Jun 5;15(6):e1002574. doi: 10.1371/journal.pmed.1002574. eCollection 2018 Jun.
PubMed 29870531Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006 Aug 16;296(7):782-93. doi: 10.1001/jama.296.7.782.
PubMed 16905784Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, Aldrovandi GM, Stringer EM, Kankasa C, Safrit JT, Stringer JS. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet. 2007 Nov 17;370(9600):1698-705. doi: 10.1016/S0140-6736(07)61605-5. Epub 2007 Nov 7.
PubMed 17997151Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007 Oct 24;298(16):1888-99. doi: 10.1001/jama.298.16.1888.
PubMed 17954540Geldsetzer P, Francis JM, Sando D, Asmus G, Lema IA, Mboggo E, Koda H, Lwezaula S, Ambikapathi R, Fawzi W, Ulenga N, Barnighausen T. Community delivery of antiretroviral drugs: A non-inferiority cluster-randomized pragmatic trial in Dar es Salaam, Tanzania. PLoS Med. 2018 Sep 19;15(9):e1002659. doi: 10.1371/journal.pmed.1002659. eCollection 2018 Sep.
PubMed 30231024Mukamba N, Beres LK, Mwamba C, Law JW, Topp SM, Simbeza S, Sikombe K, Padian N, Holmes CB, Geng EH, Sikazwe I. How might improved estimates of HIV programme outcomes influence practice? A formative study of evidence, dissemination and response. Health Res Policy Syst. 2020 Oct 16;18(1):121. doi: 10.1186/s12961-020-00640-7.
PubMed 33066785Wachira J, Middlestadt S, Reece M, Peng CY, Braitstein P. Physician communication behaviors from the perspective of adult HIV patients in Kenya. Int J Qual Health Care. 2014 Apr;26(2):190-7. doi: 10.1093/intqhc/mzu004. Epub 2014 Feb 10.
PubMed 24519123Wachira J, Middlestadt S, Reece M, Peng CY, Braitstein P. Psychometric Assessment of a Physician-Patient Communication Behaviors Scale: The Perspective of Adult HIV Patients in Kenya. AIDS Res Treat. 2013;2013:706191. doi: 10.1155/2013/706191. Epub 2013 Feb 11.
PubMed 23476754
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimizing Care Delivery to Support Reengagement in PLWH Returning to HIV Care After Treatment Lapses in Zambia
- ClinicalTrials.gov ID
- NCT06803316
- Acronym / sponsor ID
- Reengagement / REENGAGEMENT (R34)
- Keywords
- HIV, Antiretroviral Therapy (ART), Retention, Reengagement
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 658 participants (actual)
- Lead sponsor
- Centre for Infectious Disease Research in ZambiaUniversity, hospital or other
- Collaborators
- Washington University School of Medicine, National Institute of Mental Health (NIMH)
- Study start
- 10 Aug 2022 (actual)
- Primary completion
- 31 Jul 2025 (actual)
- Study completion
- 31 Jul 2025 (actual)
- First posted
- 31 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
1.0 Introduction
The scale-up of human immunodeficiency virus (HIV) treatment services has expanded rapidly in Zambia, facilitated by evolution of the HIV response from centralized services to decentralized care and now towards differentiated service delivery models. Nevertheless, optimal effectiveness remains elusive because timely engagement in care to allow uninterrupted access to antiretroviral therapy (ART) and sustained viral suppression remain incomplete. Ensuring retention in care is especially relevant since greater numbers of HIV-infected patients are also entering a phase of long-term follow-up. After receiving access to HIV care, a high fraction become lost to follow up with some estimates as high as 25-40%, which is defined as the outcome where the patient has missed their appointment by 30 days and has not died or seeking care at a different healthcare facility, or disengaged from care altogether. Research also suggests that LTFU outcomes are driven by a multitude of factors including structural and clinic-based barriers, individual and community-based barriers. A new generation of innovative interventions is needed to overcome these multifaceted barriers to optimization of the engagement of HIV infected patients with the public health systems that have emerged to serve them. Sustained retention is a critical determinant of viral suppression for PLWH, but treatment interruptions put them at high risk for viremia and mortality.
Emerging evidence clearly demonstrates that people living with HIV (PLWH) frequently transition in and out of care over time in sub-Saharan Africa and the time of re-engagement in HIV care presents a critical opportunity to break these ongoing cycles of disengagement. Since the presence of specific barriers leads to disengagement from care for some patients, designing strategies targeting these barriers can offer up a natural prospect for ensuring long-term care engagement. It is evident that the strategies required to initiate a patient into care would be markedly different than those to ensure reengagement in care. Even when PLWH return to care after loss to follow-up (LTFU), rates of repeat LTFU in the future are very high. Our preliminary data from Zambia suggests that 30% become LTFU again within 6 months of return, and that 50% of those who are currently LTFU have previously cycled in and out of care. Few interventions have successfully improved return rates among those LTFU but an estimated 50-70% return to care on their own by one year. Strategies for intervening at the time of reengagement in care are urgently needed to break these cycles of disengagement in this high-risk population.
To address these knowledge gaps, we seek to engage key stakeholders in developing a reengagement program to address critical barriers to reengagement and strengthen long-term reengagement in care. This reengagement study will provide important direction for future interventions and studies to formally test this health-system intervention for patients reengaging in HIV care after LTFU.
1.1 Rationale
Evidence from our groups as well as throughout Africa highlight the critical needs to strengthen programs for reengagement into HIV care. It is well documented that PLWH frequently transition in and out of care over time in sub-Saharan Africa leading to treatment interruptions that can put them at high risk for viremia and mortality. Among those who return to care after loss to follow-up (LTFU), rates of repeat LTFU in the future are also very high with up to 30% becoming LTFU again within 6 months of return. Additionally, among those who are currently LTFU, 50% have previously cycled in and out of care indicating missed opportunities to intervene. As an estimated 50-70% of those LTFU return to care on their own by one year strategies for intervening at the time of reengagement in care are very promising to help break these cycles of disengagement in this high-risk population.
1.2 Research Question
What are the most important needs and preferences of patients and providers for a multicomponent reengagement strategy?
2.0 Study Objectives
2.1 Study Specific Aim
To develop a reengagement strategy that meets the needs and preferences of patients and providers in public health HIV settings.
2.2 Scientific Objectives
The study has three main objectives. These include:
- Assess patient and provider needs and preferences for reengagement strategies using best-worse scaling experiments.
- Assess patient and provider needs and preferences for reengagement strategies using qualitative methods.
- Develop an intervention to optimize the experience of reengagement in HIV care using human-centered design.
Detailed description
Purpose of the research: To systematically evaluate the overall patient experience and its effect on retention in care and virologic suppression via multiple novel measurement modalities in public ART clinics in Zambia and make public health HIV treatment more patient centred, manage and enhance perceptions of quality, and strengthen engagement to optimize treatment.
Statement of the problem: Evidence from our previous Betterinfo study (004-06-14) as well as throughout sub-Saharan Africa points to patient experience as a crucial area for improvement. These data offer a simple synthesis and strategy for improvements. That is, when patients perceive encounters with the health system to be high-quality, respectful, accessible, responsive, and effective, engagement is strengthened.
Rationale/Justification for the study: This study will provide important direction for future interventions to implement more patient-centred care in the current public health HIV infrastructure, as it will fill important knowledge gaps regarding clinic-based barriers to care.
Research questions:
- What are the most important needs and preferences of patients and providers for a multicomponent reengagement strategy?
Main Aim: To develop a reengagement strategy that meets the needs and preferences of patients and providers in public health HIV settings.
Specific objectives: The study has three main objectives. These include:
- Assess patient and provider needs and preferences for reengagement strategies using best-worse scaling experiments.
- Assess patient and provider needs and preferences for reengagement strategies using qualitative methods.
- Develop an intervention to optimize the experience of reengagement in HIV care using human-centered design.
Methodology (design, sampling, data collection methods and tools):
Objective 1: Investigators will conduct best-worse scaling experiments among patients (n=400) and HCWs (n=200) to quantify relative preferences for the contents and implementation attributes for strategies to improve post-return care delivery.
Objective 2: Guided by the Consolidated Framework for Implementation Research and the Socioecological Model, investigators will use qualitative methods to explore how to optimize the experiences of care delivery after returning to HIV care. Investigators will conduct semi-structured interviews with PLWH who reengaged in the past 6 months and did (n=15) and did not (n=15) remain in care as well as focus group discussions with HCWs (i.e., physicians, nurses, clinic leadership; 6 FGDs, n=8-10 each)
Objective 3: Using principles from human-centered design and intervention mapping, investigators will synthesize findings from Aim 1 and co-develop a multicomponent reengagement coordination implementation strategy focused on:
- improving the patient experience of reengagement,
- optimizing ART re-initiation and viral load monitoring post-return, and
- offering services tailored to initial LTFU reasons to support sustained engagement.
Investigators will employ an iterative human-centered process involving key stakeholders (reengaged PLWH, HCWs, clinic leadership, Ministry of Health) to co-design the key components (e.g., practice facilitation and audit-feedback for providers, tailored services for patients) and develop a locally appropriate and acceptable intervention prototype.
Data management issues (data management plan, analysis and storage):
Objective 1: Investigators will summarize routine survey responses using frequency and proportions. Investigators will evaluate the BWS exercise using count analysis and BWS scores for individuals (difference in number of times item scored best and worst/number of times item appears) and, aggregate score for the population (mean population score f rescaled to 100, presented as forest plots). Investigators will use standard statistical techniques to explore preference heterogeneity and will perform subgroups analyses across characteristics including reason for initial LTFU (i.e., structural, clinic-based, psychosocial), sex, age, and HCW cadre. Data will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Data will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Once data are linked to SmartCare records using ART numbers, identifying information will be removed in order to maintain confidentiality.
Objective 2: Recordings will be transcribed by trained CIDRZ RAs, and if necessary, translated into English with subsequent back translation or a second-party review of sections of the translation. With the transcribed audio-recording data, investigators will code and computerize for analysis. The audio recordings, data collection tools and memos will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Identifying information will be removed during transcription in order to maintain confidentiality. Transcriptions will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Investigators will use thematic content analysis across all data to analyze the data using qualitative software (e.g. Dedoose or NVivo). Qualitative data analysis consists of searching for patterns in data and conceptualizing ideas that help explain the presence of those patterns. For patient interviews, investigators will also employ a narrative analysis where we read each interview as a whole, without regard to individual codes, to create a more global understanding of the "point of the story".
Objective 3: Implementation of HCD generally follows an iterative framework of inquiry, problem-solving and co-design. Diverse methods are employed in each of these phases including system/stakeholder mapping, compiling secondary data, user journey maps/personas, cognitive sorting and ranking, and iterative prototyping. Investigators will collect detailed meeting minutes, visual outputs created from participatory activities, written reflections from participants, and take careful notes during the design team meetings and workshops. Investigators will qualitatively analyze data gathered during the HCD co-creation activities using affinity mapping and rapid thematic analysis. This will occur in between co-creation workshops to identify design opportunities to discuss in future workshops and also after the close of the final workshop.
Participants to be recruited and inclusion criteria: This study will be conducted in Lusaka province at four Ministry of Health-operated facilities that are supported by the Centre for Infectious Disease Research in Zambia (CIDRZ). All participants must give consent to participate. Additional inclusion criteria, sampling and sample size are as follows:
Objective 1 PLHW reengaging in HIV care: Investigators will enroll up to 400 PLWH (age≥18 years) who are reengaging in care from four health care facilities supported by CIDRZ in Lusaka. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 60 days late to their last appointment per Zambian HIV guidelines. Investigators will include PLWH returning to their original clinic or as a transfer from a different facility. Investigators will recruit participants on the day of return to care using similar recruitment procedures as Objective 1. Eligible participants will be identified by clinical staff during their routine clinic visit, and trained CIDRZ research assistants (RAs) will then recruit and enroll them in a private area as they wait for their clinical consultation or drug pick-up. Investigators have used this approach to successfully recruit over 300 returning patients to date as part of an ongoing study (BMFG OPP1166485).
Healthcare Workers: Investigators will enroll up to 200 health care workers who participate in the care of PLWH across these four health care facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. Investigators will use convenience sampling to identify HCW for surveys using procedures that have been well-established by our study team in Zambia to successfully recruit HCWs. Investigators will first engage with clinic leadership to identify appropriate times for recruitment and survey administration.
Objective 2 Patient Semi-Structured Interviews: Investigators will recruit PLWH (age≥18 years) who reengaged in care within the past 6 months at four health care facilities supported by CIDRZ in Lusaka and subsequently did (n=15) and did not (n=15) remain in care. Investigators will recruit individuals amongst our survey cohort who agreed to be contacted in the future for qualitative interviews. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 60 days late to their last appointment per Zambian HIV guidelines. Investigators will include PLWH returning to their original clinic or as a transfer from a different facility. Investigators will use purposive and maximum variation sampling of participants to ensure participants represent a range of perspectives (i.e., we will recruit participants based on patient characteristics such as gender and age to ensure a range of perspectives as well as barriers to care identified during surveys in Objective 1).
Eligible participants who remained in care will be identified by clinical staff during their routine clinic visit, and trained CIDRZ research assistants (RAs) will then recruit and enroll them in a private area. Those who become LTFU within 6-months of return will be identified in the EHR, through clinic logs, and through routine tracing procedures already in place. These individuals will be contacted via phone and recruited; if they agree to participate, they will then be interviewed in-person in mutually agreed private location. Our research team and CIDRZ has previously used these procedures to recruit LTFU participants for in-depth interviews.
Healthcare workers: The target population for this objective are all health care workers delivery HIV care at our study facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. Investigators will use convenience sampling to identify HCW for focus groups discussions among HCWs (i.e., clinicians, nurses, lay HCWs, pharmacists, clinic leadership) at four facilities. Investigators will use procedures that have been well-established by our study team in Zambia to successfully recruit HCWs. Investigators will first engage with clinic leadership to identify appropriate times for recruitment and interviews. Investigators will conduct 6 FGDs (N=8-10 each), which will be organized by HCW cadre to ensure that there is open discussion with minimal concern for power hierarchies.
Objective 3 Investigators will recruit reengaged patients (beneficiaries) and HCWs (implementers). Informed by Aim 1 findings, investigators will also use stakeholder mapping to identify key groups who may influence reengagement behaviors and outcomes among PLWH and HCWs and purposefully recruit from these groups from the four facilities in Aim 1. A priori, we expect to engage with patients who have reengaged in care (n=5-10), health care workers (n=5-10) (as beneficiaries and implementers, respectively, of the interventions) and clinic leadership (n=5) and Ministry of Health administrators (n=1-2) as influencers. Our team has experience recruiting and engaging these multilevel stakeholders in HCD workshops82. Recruitment will be similar to procedures outlined in previous objectives. Participants will be given K100 for travel reimbursement.
Ethical considerations: Investigators will submit the proposed protocol, the informed consent documents, data collection tools and any subsequent modifications for review and approval. Also, the Washington University School of Medicine (WUSM) Institutional Review Board (IRB) will provide ethical reviews and regulatory oversight through a reliance agreement with the other collaborating US institutions. Investigators request an expedited review and will obtain written informed consent from participants agreeing to participate in the following study activities:
- Patient Surveys and In-depth Interviews with patients.
- Health care worker surveys and Focus group discussions
Permission will be sought from national, provincial, district and facility Ministry of Health authorities to conduct the study in public health facilities. The study will follow standard Ministry of Health guidelines to engage with staff, patients and patient records. Investigators will also ensure that all staff involved with study data are trained in Good Clinical Practice and Human Subjects Protection.
Timelines: The study proposes to implement the study intervention over a course of 18 months. Detailed timeline with activities are outlined in the proposed protocol.
Plans to disseminate research findings:
In-order to maximise the benefit of the study findings without delay, the study findings will be shared with key stakeholders such as Ministry of Health and community leaders. Study findings will be disseminated at national, international meetings, conferences and in scientific journals. Permission will be sought from National Health Research Authority prior to any publications or any form of dissemination being made.
POSSIBLE BENEFITS TO PARTICIPANTS:
No direct benefits to participants are expected. Participants may benefit in that the aim provides a direct outlet for their input to be translated into intervention design and future policy decisions. Participants may benefit from improvements in quality of care provided and increased understanding from health care workers resulting from this work. Those disengaged from care may benefit from tracing and follow up by trained counsellors and may decide to re-engage in care. Participants will also receive a small reimbursement (approximately K 100) for their transport and time spent to participate in semi-structured interviews or FGDs. Health care workers and facilities may benefit from understanding patient expectations and from learning how data can be used to interpret and improve clinic practices. Patients may also benefit from the knowledge that their perspectives are valued for improving care delivery. The Zambian Ministry of Health will benefit from the coaching provided by the research team, which may serve to improve the working environment for health care workers and care delivered to patients. The HCD process will result in developing a reengagement strategy that can improve the care of people living with HIV.
POSSIBLE RISKS TO PARTICIPANTS:
All interviews and discussion have the potential to make participants embarrassed, worried, anxious, or uncomfortable when reporting on their interactions. Participants may feel uncomfortable answering questions or discussing their HIV treatment history with the research team during semi-structured interviews or when completed surveys. The research staff will be trained to be sensitive to these areas, for example, such as discussing challenges with HIV care, livelihoods, or family. HCWs may similarly experience discomfort discussing or answering surveys pertinent to their own skills or work preferences. Some participants who are currently lost from care may be contacted via telephone to participate in interviews. This contact may have a small possible risk of involuntary disclosure of HIV status. Investigators will attempt to minimize this by training all follow up staff to be discrete and professional, ensuring that patient confidentiality is maintained at all times and identities are verified prior to providing additional information.
During FGDs, colleagues may also be present and HCWs may fear reprisal if confidentiality is breached. FGDs will be organized by HCW cadre to be sensitive of power dynamics and ensure comfort in openly discussing pertinent topics.
Participants in HCD workshops may also feel uncomfortable answering questions and participating in discussions regarding the challenges about receiving and/or delivering HIV care. Patients may fear negative attitudes from HCWs and HCWs may worry about retribution from their superiors. Workshop composition will be attentive to power dynamics, ensuring participants are engaged on days of the workshop or through sub-groups such that they are free to share their opinions and act as co-designers (e.g., patients or HCWs feel free to share thoughts in presence of health care administrators).
Details of how these risks will be minimized are outlined in the protocol.
POSSIBLE BENEFITS TO THE COMMUNITY:
The potential benefits to society may be an increased understanding of how the process of reengagement can be improved to facilitate ongoing sustained engagement in care and overall HIV outcomes and the needs and preferences of key stakeholders.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 308 Days
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient Semi-Structured Interviews: We will recruit PLWH (age≥18 years) who reengaged in care within the past 6 months at four health care facilities supported by CIDRZ in Lusaka and subsequently did (n=15) and did not (n=15) remain in care. We will recruit individuals amongst our survey cohort who agreed to be contacted in the future for qualitative interviews. Reengaging in care will be defined as returning to care after being considered LTFU, which is defined as being greater than 30 days late to their last appointment per Zambian HIV guidelines and or not having ART drugs for greater than 30 days. Healthcare workers: The target population for this objective are all health care workers involved in delivery HIV care at our study facilities. This includes clinic leadership (i.e., in-charge), medical officers, clinical officers, nurses, lay health care workers, and pharmacists. We use convenience sampling to identify HCW for in-depth interviews (IDIs) (i.e., clinicians, nurses,
Key inclusion criteria (5 listed)
- Participant must be over 18 years of age.
- Should be LTFU for greater than 30 days or
- Should not have had ART drugs for greater than 30 days;
- Pregnant women who meet inclusion criteria
- Illiterate participants willing to provide informed consent in Nyanja or Bemba provided there is a witness.
Key exclusion criteria (4 listed)
- Participant is too sick i.e., failing to talk, general discomfort and emergency cases).
- Participant is unable to provide written informed consent in English, Nyanja or Bemba.
- Participant who is drunk or mentally ill.
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Retention
Time frame: 2022 to 2025
Number of participants who reengaged (less than 30 days late to their scheduled appointments) and were consistently taking their medication
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2026.
- Background: PubMed 32667277Vindrola-Padros C, Johnson GA. Rapid Techniques in Qualitative Research: A Critical Review of the Literature. Qual Health Res. 2020 Aug;30(10):1596-1604. doi: 10.1177/1049732320921835.
- Background: PubMed 27509291Koenig CJ, Abraham T, Zamora KA, Hill C, Kelly PA, Uddo M, Hamilton M, Pyne JM, Seal KH. Pre-Implementation Strategies to Adapt and Implement a Veteran Peer Coaching Intervention to Improve Mental Health Treatment Engagement Among Rural Veterans. J Rural Health. 2016 Sep;32(4):418-428. doi: 10.1111/jrh.12201. Epub 2016 Aug 10.
- Background: PubMed 15493211Higginbottom GM. Sampling issues in qualitative research. Nurse Res. 2004;12(1):7-19. doi: 10.7748/nr2004.07.12.1.7.c5927.
- Background: PubMed 24193818Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Health. 2015 Sep;42(5):533-44. doi: 10.1007/s10488-013-0528-y.
- Background: PubMed 29635466Roy M, Holmes C, Sikazwe I, Savory T, Mwanza MW, Bolton Moore C, Mulenga K, Czaicki N, Glidden DV, Padian N, Geng E. Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia. Clin Infect Dis. 2018 Sep 28;67(8):1269-1277. doi: 10.1093/cid/ciy285.
- Background: PubMed 29329301Holmes CB, Sikazwe I, Sikombe K, Eshun-Wilson I, Czaicki N, Beres LK, Mukamba N, Simbeza S, Bolton Moore C, Hantuba C, Mwaba P, Phiri C, Padian N, Glidden DV, Geng E. Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey. PLoS Med. 2018 Jan 12;15(1):e1002489. doi: 10.1371/journal.pmed.1002489. eCollection 2018 Jan.
- Background: PubMed 29020295Mody A, Roy M, Sikombe K, Savory T, Holmes C, Bolton-Moore C, Padian N, Sikazwe I, Geng E. Improved Retention With 6-Month Clinic Return Intervals for Stable Human Immunodeficiency Virus-Infected Patients in Zambia. Clin Infect Dis. 2018 Jan 6;66(2):237-243. doi: 10.1093/cid/cix756.
- Background: PubMed 29870531Mody A, Sikazwe I, Czaicki NL, Wa Mwanza M, Savory T, Sikombe K, Beres LK, Somwe P, Roy M, Pry JM, Padian N, Bolton-Moore C, Holmes CB, Geng EH. Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia. PLoS Med. 2018 Jun 5;15(6):e1002574. doi: 10.1371/journal.pmed.1002574. eCollection 2018 Jun.
- Background: PubMed 16905784Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006 Aug 16;296(7):782-93. doi: 10.1001/jama.296.7.782.
- Background: PubMed 17997151Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, Aldrovandi GM, Stringer EM, Kankasa C, Safrit JT, Stringer JS. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet. 2007 Nov 17;370(9600):1698-705. doi: 10.1016/S0140-6736(07)61605-5. Epub 2007 Nov 7.
- Background: PubMed 17954540Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007 Oct 24;298(16):1888-99. doi: 10.1001/jama.298.16.1888.
- Background: PubMed 30231024Geldsetzer P, Francis JM, Sando D, Asmus G, Lema IA, Mboggo E, Koda H, Lwezaula S, Ambikapathi R, Fawzi W, Ulenga N, Barnighausen T. Community delivery of antiretroviral drugs: A non-inferiority cluster-randomized pragmatic trial in Dar es Salaam, Tanzania. PLoS Med. 2018 Sep 19;15(9):e1002659. doi: 10.1371/journal.pmed.1002659. eCollection 2018 Sep.
- Individual participant dataSharing planned: Yes. Data will be kept in a secure and locked file until the interviews are transcribed and the transcription is finalized, after which the recordings and notes will be destroyed. Data will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis. Once data are linked to SmartCare records using ART numbers, identifying information will be removed in order to maintain confidentiality. Similarly, transcriptions will be kept in a password-protected computer file that will only be accessible to members of the research team for data analysis.
Related trials for HIV Antiretroviral Therapy (ART) Adherence
Active, not recruiting
Cash Transfers to Pregnant Women With HIV
HIV, Pregnancy
Not yet recruiting
Pilot of an Intervention to Reduce Alcohol Use and Improve ART Adherence Among Men Living With HIV With Pregnant Partners in Uganda.
HIV Antiretroviral Therapy (ART) Adherence, Alcohol Consumption
Active, not recruiting
Developing and Testing a Digital Health Tool for INterseCtional Stigma Assessment and Reduction at Multiple Levels and mUltiple DimEnsions (INCLUDE) to Improve HIV Care in ART Centers in Nepal
HIV Care Loss to Followup, HIV Antiretroviral Therapy (ART) Adherence
Not yet recruiting
Improving the HIV Care Continuum With mHealth Technology
HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence
Recruiting
Hybrid Type-1 Effectiveness-Implementation Trial of Motivation Matters!
HIV Antiretroviral Therapy (ART) Adherence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Izukanji Sikazwe, Medical Officer principal investigator
Centre for Infectious Disease Research in Zambia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV Antiretroviral Therapy (ART) Adherence, run by Centre for Infectious Disease Research in Zambia at 1 site in Zambia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Zambia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retention (time frame: 2022 to 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06803316, which also lists 85 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026; AzTrials last refreshed its copy on 3 Nov 2026.